Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom.
Endocrine Research Center, Institute of Endocrinology & Metabolism, Iran University of Medical Sciences, Tehran, Iran.
PLoS One. 2015 Jul 22;10(7):e0132505. doi: 10.1371/journal.pone.0132505. eCollection 2015.
The aim of this study was to estimate the economic burden of diabetes mellitus (DM) in Iran from 2009 to 2030.
A Markov micro-simulation (MM) model was developed to predict the DM population size and associated economic burden. Age- and sex-specific prevalence and incidence of diagnosed and undiagnosed DM were derived from national health surveys. A systematic review was performed to identify the cost of diabetes in Iran and the mean annual direct and indirect costs of patients with DM were estimated using a random-effect Bayesian meta-analysis. Face, internal, cross and predictive validity of the MM model were assessed by consulting an expert group, performing sensitivity analysis (SA) and comparing model results with published literature and national survey reports. Sensitivity analysis was also performed to explore the effect of uncertainty in the model.
We estimated 3.78 million cases of DM (2.74 million diagnosed and 1.04 million undiagnosed) in Iran in 2009. This number is expected to rise to 9.24 million cases (6.73 million diagnosed and 2.50 million undiagnosed) by 2030. The mean annual direct and indirect costs of patients with DM in 2009 were US$ 556 (posterior standard deviation, 221) and US$ 689 (619), respectively. Total estimated annual cost of DM was $3.64 (2009 US$) billion (including US$1.71 billion direct and US$1.93 billion indirect costs) in 2009 and is predicted to increase to $9.0 (in 2009 US$) billion (including US$4.2 billion direct and US$4.8 billion indirect costs) by 2030.
The economic burden of DM in Iran is predicted to increase markedly in the coming decades. Identification and implementation of effective strategies to prevent and manage DM should be considered as a public health priority.
本研究旨在估算 2009 年至 2030 年期间伊朗糖尿病(DM)的经济负担。
开发了马尔可夫微观模拟(MM)模型来预测 DM 人群规模和相关的经济负担。使用全国健康调查数据,推导出年龄和性别特定的确诊和未确诊 DM 的患病率和发病率。进行了系统评价,以确定伊朗糖尿病的成本,使用随机效应贝叶斯荟萃分析估计 DM 患者的平均年直接和间接成本。通过咨询专家组、进行敏感性分析(SA)和将模型结果与已发表文献和国家调查报告进行比较,评估 MM 模型的表面、内部、交叉和预测有效性。还进行了敏感性分析,以探讨模型不确定性的影响。
我们估计 2009 年伊朗有 378 万例 DM(274 万例确诊,104 万例未确诊)。到 2030 年,这一数字预计将上升至 924 万例(673 万例确诊,250 万例未确诊)。2009 年 DM 患者的平均年直接和间接费用分别为 556 美元(后验标准差 221 美元)和 689 美元(619 美元)。2009 年 DM 的总估计年度费用为 36.4 亿美元(2009 年美元)(包括 17.1 亿美元的直接费用和 19.3 亿美元的间接费用),预计到 2030 年将增加到 90 亿美元(2009 年美元)(包括 42 亿美元的直接费用和 48 亿美元的间接费用)。
未来几十年,伊朗 DM 的经济负担预计将显著增加。应考虑将确定和实施有效预防和管理 DM 的策略作为公共卫生的优先事项。